Back to search

Peptide record

TPDB92025

Pepfect 3 Stearyl-TP10 PF3 PF6 Antibacterial Anticancer Antifungal Antiparasitic Blood-Brain Barrier Cell-penetrating Peptides Hemolysis Toxicity standard
21 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB92025
Pepfect 3 Stearyl-TP10 PF3 PF6
Antibacterial Anticancer Antifungal Antiparasitic Blood-Brain Barrier Cell-penetrating Peptides Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides Delivery and barrier-penetrating peptides
AntiBP3 dbAMP Peptipedia Antifungipept CAFPdb dbAMP 3.0 i2APP B3Pred BBPpredict CellPPD CellPPD-MOD CPPsite3.0 PerseuCPP HemoPI Hemolytic2 PD_Hemolysis
standard
No
A 21-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, Peptipedia, and other sources, with an available 3D structural model.
C-terminal: Amidation N-terminal: Stearylation
Sequence
AGYLLGKINLKALAALAKKIL-NH2
Physicochemical Analysis
C104H184N26O24
RDCEQHMFPSTWV
L
2182.76
10.64
4
0
14
+4
-1.37
0.933
172.38
Mammalian: 4.4 hour Yeast: >20 hour E.coli: >10 hour
1490
68.26
2
Residue Composition
number
5
A
0
R
1
N
0
D
0
C
0
E
0
Q
2
G
0
H
2
I
6
L
4
K
0
M
0
F
0
P
0
S
0
T
0
W
1
Y
0
V
Amino Acid Distribution
A: 5 R: 0 N: 1 D: 0 C: 0 E: 0 Q: 0 G: 2 H: 0 I: 2 L: 6 K: 4 M: 0 F: 0 P: 0 S: 0 T: 0 W: 0 Y: 1 V: 0
Chemical Descriptors
21
C104H184N26O24
2182.76
10.64
+4
-1.37
0.933
Amidation
Modified L
Amphipathic
Linear
Stearylation
N[C@@H](C)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)O N[C@@H](CCCN=C)C(=O)N[C@@H](CC1=C(C(=NC1)C)CC)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CC1=CN=C(C)/C/1=C\C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CC1=C(C(=NC1)C)CC)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CC1=CN=C(C)/C/1=C\C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CC1=CN=C(C)/C/1=C\C)C(=O)O N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CC1=C(C(=NC1)C)CC)C(=O)N[C@@H](CC1=C(C(=NC1)C)CC)C(=O)N[C@@H](CC1=C(C(=NC1)C)CC)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)O N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CC1=C(C(=NC1)C)CC)C(=O)N[C@@H](CC1=CN=C(C)/C/1=C\C)C(=O)N[C@@H](CC1=CN=C(C)/C/1=C\C)C(=O)N[C@@H](CC1=C(C(=NC1)C)CC)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)O N[C@@H](CCCN=C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=C(C(=NC1)C)CC)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CN=C(C)/C/1=C\C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=C(C(=NC1)C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O
Evidence Records 9 records
Evidence 1 Activity

Activity

Cell-penetrating Peptides

Target

Hela pLuc 705 cells

Source & Reference

CPPsite3.0
CPPsite3
EP 2 491 952 A1

Other

Source Activity Label Source Definition
Cell-penetrating Peptides
CPPsite3.0 experimentally validated cell-penetrating peptide annotation.
Non-natural residues Linear Modified Amphipathic
Protein derived
Nucleic acid (SCO)
Endocytosis
In vitro
Evidence 2 Activity

Activity

Cell-penetrating Peptides

Target

HeLa cells

Source & Reference

CPPsite3.0
CPPsite3
US 2014/0140929 A1

Other

Non-natural residues Linear Modified Amphipathic
Synthetic
Nucelic acid (pGL3 plasmid, SCO)
Endocytosis
In vitro
Evidence 3 Activity

Activity

Cell-penetrating Peptides

Target

HeLa Pluc 705 Cells

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L Amphipathic
Synthetic
Splice correcting oligonucleotide (PS-20-OMe SCO)
Fold increase in activity over treatment with oligonucleotide alone.
In vitro
CTTTSCCCCHHHHHTGGGGTC
Evidence 4 Activity

Activity

Cell-penetrating Peptides

Target

HeLa, U87-Mg, N2A And Ht1082

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L Amphipathic
Synthetic
Cy5-labled pDNA
Nucleus
Endocytosis
In vitro
CTTTSCCCCHHHHHTGGGGTC
Evidence 5 Activity

Activity

Cell-penetrating Peptides

Target

U87 Mg-Luc2

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L Amphipathic
Synthetic
Small interfering RNAs (siRNA)
In vitro
CCCSSCCCCC
Evidence 6 Activity

Activity

Cell-penetrating Peptides

Target

U87 Mg-Luc2

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L Amphipathic
Synthetic
Small interfering RNAs (siRNA)
In vitro
CCCCCSCCTTCC
Evidence 7 Activity

Activity

Cell-penetrating Peptides

Target

CHO Cells

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L
Synthetic
FITC-labeled pGL3 plasmid
In vitro
CCCCTHHHHTTTTTTC
Evidence 8 Activity

Activity

Cell-penetrating Peptides

Target

Endometriotic Primary Cells, U-87Mg, Ht1080

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L Amphipathic
Synthetic
siRNAs against RRM2 (siRRM2) and VEGF (siVEGF) and danazol
In vitro
CCCCCSSSCCCCCCBSSSCCSSBCCCTTCCCSSCCC
Evidence 9 Activity

Activity

Cell-penetrating Peptides

Target

HeLa pLuc705 cells

Source & Reference

CPPsite3.0
CPPsite3

Other

Non-natural residues Linear L Amphipathic
Synthetic
SR-A3s and SR-A5s
Cytoplasm
In vitro
Additional Detail Fields 1 fields
CTTTSCCCCHHHHHTGGGGTC CCCSSCCCCC CCCCCSCCTTCC CCCCTHHHHTTTTTTC CCCCCSSSCCCCCCBSSSCCSSBCCCTTCCCSSCCC